Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics

I Lingvay, K Brown‐Frandsen, HM Colhoun… - …, 2023 - Wiley Online Library
Objective This paper describes the baseline characteristics of the Semaglutide Effects on
Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) study, one of the …
被引用次数：57 相关文章

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics.

I Lingvay, K Brown‐Frandsen… - Obesity …, 2023 - search.ebscohost.com
Objective: This paper describes the baseline characteristics of the Semaglutide Effects on
Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) study, one of the …

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics

SELECT Study Group - Obesity, 2023 - scholars.northwestern.edu
Objective: This paper describes the baseline characteristics of the Semaglutide Effects on
Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) study, one of the …

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics

SELECT Study Group - Obesity, 2023 - utsouthwestern.elsevierpure.com
Objective: This paper describes the baseline characteristics of the Semaglutide Effects on
Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) study, one of the …

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics

SELECT Study Group - Obesity, 2023 - researchinformation.amsterdamumc …
Objective: This paper describes the baseline characteristics of the Semaglutide Effects on
Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) study, one of the …

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics

I Lingvay, K Brown-Frandsen, HM Colhoun… - Obesity, 2023 - discovery.ucl.ac.uk
Objective: This paper describes the baseline characteristics of the Semaglutide Effects on
Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) study, one of the …

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics

I Lingvay, K Brown-Frandsen, HM Colhoun… - …, 2023 - search.proquest.com
Objective: This paper describes the baseline characteristics of the Semaglutide Effects on
Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) study, one of the …
[HTML] nih.gov

[HTML][HTML] Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics

I Lingvay, K Brown‐Frandsen, HM Colhoun… - Obesity (Silver Spring …, 2023 - ncbi.nlm.nih.gov
Objective This paper describes the baseline characteristics of the Semaglutide Effects on
Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) study, one of the …

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics

I Lingvay, K Brown-Frandsen… - … (Silver Spring, Md …, 2023 - pubmed.ncbi.nlm.nih.gov
Objective This paper describes the baseline characteristics of the Semaglutide Effects on
Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) study, one of the …

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics.

I Lingvay, K Brown-Frandsen, HM Colhoun… - Obesity (Silver Spring …, 2022 - europepmc.org
This paper describes the baseline characteristics of the Semaglutide Effects on Heart
Disease and Stroke in Patients with Overweight or Obesity (SELECT) study, one of the …